A study to investigate effects of Peptide ingestion on lowering blood pressure in the subjects with high normal blood pressure or grade 1 hypertension: a randomized, double blind, placebo controlled study.

A study to investigate effects of Peptide ingestion on lowering blood pressure in the subjects with high normal blood pressure or grade 1 hypertension: a randomized, double blind, placebo controlled study. - A study to assess the effects of Peptide ingestion on lowering blood pressure.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024786

Enrollment

120

Registered

2016-11-21

Start date

2016-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Ingestion of peptide for 12 weeks Ingestion of placebo for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with high normal blood pressure (systolic BP from 130 to 139/ or diastolic BP from 85 to 89 mm Hg) or grade 1 hypertension (systolic BP from 140 to 159/ or diastolic BP from 90 to 99 mm Hg)

Exclusion criteria

Exclusion criteria: (1) Subjects who have history or receiving treatment of serious disease (2) Subject who is under medication for diabetes, hypertension or dyslipidemia (3) Subject with a history of serious allergy to medicine and food (4) Subject who is pregnant or under lactation, or who is expected to be pregnant during the study (5) Heavy smoker and heavy drinker, or subject with irregular lifestyle (6) Subject who is ineligible due to physician's judgment based on background of subject, physical finding, interview

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure and diastolic blood pressure	—

Secondary

Measure	Time frame
Pulse Wave Velocity	—

Countries

Japan

Contacts

Public ContactShigeru Imai

CROee.INC Evidence Division

imai@croee.com03-5953-2108

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026